CHINO HILLS, CALIFORNIA / ACCESS Newswire / November 4, 2025 / SOHM, Inc. (OTCID:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs and gene-editing tools, a leader in Gene Editing and Cell Engineering is pleased to acknowledge recent FDA commentary and industry analyses signaling continued evolution of regulatory pathways for genome-editing technologies. These developments highlight increasing regulatory focus on precision-engineered genetic tools, non-viral delivery approaches ...